CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Collaboration revenue	$ 41,196	$ 1,595	$ 8,525
Royalty income	3,101	5,923	4,963
Research grants	0	275	488
Other revenues	80	69	72
Total revenues	44,377	7,862	14,048
Expenses:
Research and development	27,737	33,391	31,332
License fees - research and development	498	567	1,170
Royalty expense	357	624	499
General and administrative	14,944	14,602	15,214
Depreciation and amortization	545	939	1,324
Intangible impairment charge	2,676	919	0
Change in contingent consideration liability	1,500	(200)	0
Total expenses	48,257	50,842	49,539
Other Operating Income	7,250	0	0
Operating income (loss)	3,370	(42,980)	(35,491)
Other income:
Interest income	51	46	60
Total other income	51	46	60
Net income (loss) before income tax benefit	3,421	(42,934)	(35,431)
Income tax benefit	989	362	0
Net income (loss)	$ 4,410	$ (42,572)	$ (35,431)
Net income (loss) per share - basic	$ 0.06	$ (0.76)	$ (1.02)
Weighted-average shares - basic	68,185	55,798	34,754
Net income (loss) per share - diluted	$ 0.06	$ (0.76)	$ (1.02)
Weighted-average shares - diluted	68,243	55,798	34,754